Objectives
Antioxidants can reduce oxidative radicals that affect the early phase of atherogenesis, that is endothelial dysfunction. Polysaccharide Peptide (PsP) derived from
Ganoderma lucidum
has an active substance in the form of β-glucan. Previous studies have proven the PsP of
Ganoderma lucidum
as an effective antioxidant in atherosclerotic rats and shows no toxicity in animal model. This study aims to prove the effect of PsP as potent antioxidant in high risk and stable angina patients.
Method
This is a clinical trial conducted to 37 high risk and 34 stable angina patients, which were determined based on ESC Stable CAD Guidelines and Framingham risk score, with pre and post test design without control group. The parameters are superoxide dimustase (SOD) and malondialdehyde (MDA) concentration, circulating endothelial cell (CEC) and endothelial progenitor cell (EPC) counts. The patients were given PsP 750 mg/day in 3 divided dose for 90 days. Paired
t
-test was performed for normally distributed data, and Wilcoxon test for not normally distributed data, and significant level of p ≤ 0,05.
Results
SOD level in high risk patients slightly increased but not statistically significant with p = 0,22. Level of SOD in stable angina group significantly increased with p = 0,001. MDA concentration significantly reduced in high risk and stable angina patients with p = 0.000. CEC significantly reduced both in high risk and stable angina patients, with p = 0.000 in both groups. EPC count significantly reduced in high risk and stable angina with p = 0.000.
Conclusion
PsP of
Ganoderma lucidum
is a potent antioxidant against pathogenesis of atherosclerosis in stable angina and high risk patients
Lutembatcher syndrome is a rare cardiac condition characterized by a combination of the atrial septal defect (ASD; congenital or iatrogenic) and mitral stenosis (MS; congenital or acquired). Patients with Lutembatcher syndrome and adults with congenital heart disease (ACHD) in general may be at high risk when accompanied by coronavirus disease 2019 (COVID-19). Since there is no published study on the impact of COVID-19 on ACHD, little is known about management strategies in this subset of patients. Herein, we report a young adult female presented with abdominal discomfort, swollen legs, fever, cough, and dyspnea. The patient had developed palpitation and exercise intolerance five years ago but paid it no attention. Echocardiography revealed large secundum type ASD with severe MS (Wilkins score of eight) and a nasopharyngeal swab confirmed SARS-COV-2 infection. The patient was diagnosed with Lutembacher syndrome and COVID-19. Intensive treatment was given to relieve symptoms due to heart failure and to treat COVID-19 pneumonia. Patients with Lutembatcher syndrome are at a higher risk of being infected with COVID-19 and manifest into severe infections. Therefore, determining the risk of infection and the severity of COVID-19 in ACHD patients are required during the pandemic.
Background: Heart disease is the number one cause of death globally. This disease is initiation affected by autonomic dysfunction which will cause disruption of the sympathetic-parasympathetic system. Heart Rate Recovery (HRR) is used to determineautonomic dysfunction.Objective: To determine the relationship of risk factors and cardiovascular treatment to HRR values of 1 minute and 2 minutes.Methods: Cross sectional study to measure HRR 1 and 2 minute undergoing exercise treadmill test for the screening of coronary heart disease in Saiful Anwar hospital in May 2016 until September 2017. Univariate analysis was performed to determine the frequency and proportion of HRR values classified into normal groups (HRR 1 minute > 12x / minute or HRR 2 minutes > 22x / minute) and abnormal groups (HRR 2 minutes ≤ 12x / minute or HRR 2 minutes ≤ 22x / minute).We also performed bivariate analysis using comparative test (Generalized Linear Model) and correlation test (Pearson, Spearman and Eta) and multivariate linear regression analysis.Results: This study found that age, hypertension and beta blocker were significantly associated with HRR abnormalities (p<0.05). HRR 1 and HRR 2 were significantly associated with diabetes mellitus (DM) (p=0.004 and p=0.039) and beta blocker (p=0.042 and p=0.039). Then looking at the relationship of multivariate correlations found a significant correlation between age (β=-0.133, p=0.000) and DM (β=-2.617, p=0.032) at 1 minute HRR and significant correlation with age (β=-0.165, p=0.004) and beta blockers (β=-2,947, p=0.017).Conclusion: increasing of age, diabetes mellitus and beta blockers correlate with decreasing of HRR. The most influential risk factors for HRR values of 1 minute were increasing age and DM, while for HRR values of 2 minutes were increasing age and beta blockers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.